ArticleJMIR dermatology2026
Current Management and Unmet Needs in Alopecia Areata: Viewpoint From a Malaysian Perspective.
Article in JMIR dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlabelled: Alopecia areata (AA) is a chronic, immune-mediated disease characterized by nonscarring hair loss and a substantial clinical and psychosocial burden, yet it is still widely perceived as a purely cosmetic concern. In this viewpoint, we draw on the available Malaysian studies, selected international evidence, and our collective clinical experience to propose that AA warrants greater clinical, research, and policy attention in Malaysia. Malaysia-specific evidence remains limited and is derived largely from retrospective, single-center studies; nonetheless, the available data point to variable disease presentation, inconsistent use of standardized severity assessment, reliance on conventional therapies, substantial loss to follow-up, and a meaningful psychosocial impact among affected patients. Current local management appears to rely mainly on conventional therapies, while access to advanced therapies such as Janus kinase inhibitors remains constrained by affordability and reimbursement challenges. We therefore call for 5 priorities: strengthening Malaysia-specific epidemiological and real-world evidence, including through a national AA registry; adopting standardized disease-assessment tools in clinical studies and routine practice; integrating psychosocial support into AA care pathways; developing locally relevant clinical guidance; and improving public, clinician, and policymaker awareness that AA is a medical condition rather than a cosmetic concern. Together, these steps would support earlier diagnosis, more equitable access to effective treatment, and holistic, patient-centered care for adults and children living with AA in Malaysia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.